Articles Tagged With: symptoms
-
How Does the Genitourinary Syndrome of Menopause Affect Patients?
This analysis of baseline questionnaire responses from 302 individuals enrolled in the MsFLASH Vaginal Health Trial demonstrated that the most commonly reported symptoms were vaginal dryness (94%), pain with vaginal penetration (84%), vulvovaginal pain and soreness (76%), and vulvovaginal irritation (73%). The symptom most often rated severe was pain with vaginal penetration (40%).
-
Do Patients with Heart Failure Feel Better on Dapagliflozin?
An analysis of the DETERMINE studies of dapagliflozin vs. placebo in patients with heart failure showed some improvement in self-reported symptoms in those with reduced ejection fraction on dapagliflozin but not in the six-minute walk test. No improvements in symptoms or physical activity levels were found in those with preserved ejection fraction on dapagliflozin.
-
Do Patients with Heart Failure Feel Better on Dapagliflozin?
An analysis of the DETERMINE studies of dapagliflozin vs. placebo in patients with heart failure showed some improvement in self-reported symptoms in those with reduced ejection fraction on dapagliflozin but not in the six-minute walk test. No improvements in symptoms or physical activity levels were found in those with preserved ejection fraction on dapagliflozin.
-
Peak SARS-CoV-2 Viral Loads Delayed
In an effort to characterize the hypothetical utility of rapid COVID-19 antigen kits, the authors of this study examined cycle threshold values in symptomatic adults infected with SARS-CoV-2 relative to the onset of symptoms.
-
Zilucoplan Injection (Zilbrysq)
The U.S. Food and Drug Administration has approved a once-daily subcutaneously administered drug for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive. Zilucoplan is macrocyclic peptide that inhibits the cleavage of complement 5 (C5) to C5a and C5b.
-
Endometriosis and the Gut Microbiome: Nutritional Prospects in the Treatment of a Chronic Disease
Endometriosis is characterized by the presence of endometrial glands and stroma in any extrauterine site, such as the ovary, fallopian tubes, pelvic peritoneum, rectovaginal space, bowel, and, rarely, lungs and brain. Standard treatment of endometriosis may involve the use of pain relievers such as nonsteroidal anti-inflammatory drugs, hormonal therapy and modulators, and/or surgical removal of endometriotic tissue. On average, women seek consultation from three different healthcare providers over several years to receive a diagnosis of endometriosis. The delay in care results in significant long-term morbidity.
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
In this multinational, randomized, double blind, placebo-controlled trial, 522 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment as compared with placebo.
-
Treatment of Psychotic Symptoms in Alzheimer’s Disease
In a meta-analysis of several large treatment trials of patients with Alzheimer’s disease, Parkinson’s disease, and dementia with Lewy bodies, cholinesterase inhibitors demonstrated a small but statistically significant benefit in reducing psychotic symptoms.
-
Golden State: Disseminated Gonococcal Infection
The diagnosis of disseminated gonococcal infection often is delayed, but the infection can most often be readily treated with ceftriaxone. Patients often lack urogenital symptoms.
-
Brain Iron Chelation with Deferiprone in Parkinson’s Disease
In a randomized, placebo-controlled treatment trial, deferiprone administered to early, levodopa-naive Parkinson’s disease patients over 36 weeks was associated with worsening of their symptoms, in spite of imaging evidence for reduction of iron in the substantia nigra.